GLP-1 Medication and PCOS: What Women Should Know

Why GLP-1 medicines are relevant to PCOS

Polycystic ovary syndrome is, at its core, a metabolic condition as much as a reproductive one. Insulin resistance is a central driver for most women with PCOS, feeding higher androgen levels, irregular cycles and stubborn weight gain³. GLP-1 receptor agonists were designed to improve exactly this machinery — they slow gastric emptying, blunt appetite and improve the body's response to insulin — which is why they have become such a focus for women whose PCOS weight will not shift with diet and exercise alone⁴.

What the evidence shows

The large obesity trials that put these drugs on the map were not PCOS-specific, but they enrolled many women and are the best evidence for the medications themselves. In the STEP 1 trial, once-weekly semaglutide produced a mean body-weight reduction of roughly 15% over 68 weeks¹. Tirzepatide — a dual GIP/GLP-1 agonist — went further in SURMOUNT-1, with mean reductions around 20% at the highest dose². Because insulin resistance is so central to PCOS, many women and their clinicians are specifically interested in tirzepatide's metabolic effect, which is one reason we weight access to both molecules heavily in our Luna Fit Score.

What to ask a provider

The right provider for PCOS does more than mail a vial. Ask whether a licensed clinician reviews your history and runs or interprets labs; whether both semaglutide and tirzepatide are available so you are not locked into one molecule; and how titration and side effects are supported over the first months. These are the factors that separate a genuine women's-metabolic program from a prescription vending machine — and they are exactly what our top-ranked provider, CoreAge Rx, is scored on. If you would rather see the whole field lined up on that one question than read about providers one at a time, we rank every program we track on its PCOS and hormonal suitability score.

The cautions that matter for women

GLP-1 medicines are not appropriate during pregnancy or while trying to conceive, and — notably — improving insulin sensitivity can restore ovulation in women with PCOS, which can make pregnancy more likely than expected³. They can also affect absorption of oral medications. Which molecule you are offered matters here too — the dual GIP/GLP-1 agonist is the one women with insulin-resistant PCOS most often ask for by name, and our semaglutide versus tirzepatide comparison sets out what the head-to-head trial actually showed. None of this is a reason to avoid treatment; it is a reason to have it managed by a clinician who understands your hormones and goals — see our guide on GLP-1s, birth control and fertility for what that means in practice, and the rest of our women's-health evidence library for the questions this one does not cover. If you're actively pursuing pregnancy through IVF, that fertility-restoration effect raises its own timing questions our guide to GLP-1 before IVF and fertility treatment covers directly. PCOS also shares real biology with two conditions this site covers on their own: insulin resistance raises baseline gallstone risk alongside the estrogen effect already at play, covered in our gallstones guide, and a published case report has described a woman using a GLP-1 for co-occurring PCOS and idiopathic intracranial hypertension, a female-predominant headache condition our migraine and IIH guide explains. This guide is educational only and not medical advice.